Patients with Wolff-Parkinson-White syndrome who receive catheter ablation to cure their abnormal heart rhythms are just as likely as non-ablated patients to develop atrial fibrillation no matter what age they receive ablation, according to a new study.
Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat cancer patients for the second leading cause of death among cancer survivors — cardiovascular disease brought on by their treatments. Specific types of chemotherapy and chest-directed radiation therapy are known to cause cardiac dysfunction, mainly due to cardiotoxicity — the symptoms of which may not present until months or even years after cancer treatment.Â
If you enjoy this content, please share it with a colleague
Medtronic plc recently announced it received U.S. Food and Drug Administration (FDA) approval for the first and only magnetic resonance imaging (MRI)-conditional cardiac resynchronization therapy defibrillators (CRT-Ds) for the treatment of heart failure.
Imricor Medical Systems announced enrollment of the first patients in a clinical study to evaluate the Vision-MR Ablation Catheter for the treatment of atrial flutter under real-time magnetic resonance imaging (MRI) guidance.
Medtronic plc announced clinical results highlighting the strong safety and performance profile of the miniaturized Micra Transcatheter Pacing System (TPS) at Heart Rhythm 2016, the Heart Rhythm Society's 37th Annual Scientific Sessions, May 4-7 in San Francisco.
The first-ever trial using new SonR hemodynamic sensor technology proves to be safely and effectively applied in cardiac resynchronization therapy (CRT) patients.
Results from a first-of-its-kind study identify a significant increase in the incidence of atrial fibrillation (AF) among patients with pacemaker-detected sleep apnea.
